A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

ClinicalTrials.gov ID: NCT07838740

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07838740. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.

Study identification

NCT ID: NCT07838740
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Viking Therapeutics, Inc.; Industry
Enrollment: 270 participants

Conditions and interventions

Conditions

Obese Adults

Interventions

VK2735 Drug Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 18, 2025 (Actual)
Primary completion: May 2027 (Estimated)
Completion: Jul 2027 (Estimated)
Last update posted: Sep 24, 2026

2025 – 2027

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Viking Clinical Site #001	Lake Forest	California	92630	Recruiting
Viking Clinical Site #002	Miami	Florida	33147	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07838740, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 24, 2026 · Synced Nov 13, 2026